Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody

Research output: Contribution to journalArticle

Authors

Institutes & Expert groups

Documents & links

DOI

Abstract

RIT (Radioimmunotherapy) has become an attractive strategy in cancer treatment, but still faces important drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. Smaller radiolabeled antibody fragments and peptides feature highly specific target accumulation, resulting in low accumulation in healthy tissue, except for the kidneys. Nanobodies are the smallest (MW

Details

Original languageEnglish
Pages (from-to)708-720
JournalTheranostics
Volume4
Issue number7
DOIs
StatePublished - Apr 2014

Keywords

  • HER2, nanobody, targeted radionuclide therapy, 177-Lutetium

ID: 192824